

PRESS REPORT

LATTICE MEDICAL announces the success of the first breast reconstruction operation with the MATTISSE implant

A world first for breast reconstruction with a totally resorbable implant

Lille, France, September 15, 2022 - After the entry into clinical phase announced in early July 2022, LATTICE MEDICAL, announces the success of the first breast reconstruction operation with the MATTISSE implant. The operation took place on July 12 at the Institute of Clinical Oncology, Tbilisi, Georgia. It was conducted by Pr Gia Nemsdaze and his team, and in the presence of the co-founders of Lattice Medical, Pr. Pierre Guerreschi, Pr. Philippe Marchetti, (both PUPH at the University Hospital of Lille) and Mr Julien Payen.

This was an immediate breast reconstruction for a 62 year old patient suffering from breast cancer. The surgical procedure lasted one and a half hours and allowed the mastectomy to be performed, immediately followed by the breast reconstruction.

Two months after the operation, the healing is complete and the patient is in very good health.



Figure 1 - First operation with MATTISSE with Pr Nemsdaze's team at the Institute of Clinical Oncology

A 3-year clinical study in three countries

It is planned to include 50 patients in the Tide study, in Georgia, France and Spain in 8 centers. The study will be coordinated by Prof. Pierre Guerreschi from the plastic surgery department of the Lille University Hospital. This study will include an initial 8-month recruitment period. The objective of the study is to demonstrate the safety and clinical efficacy of the MATTISSE® Tissue Engineering Chamber (TEC) used in combination with autologous breast reconstruction. During the surgical procedure, the shell and base are assembled, creating a void or chamber. The TEC is implanted pre-pectorally in the breast area. A vascularized pedicled fat flap (LICAP or LTAp flap) is placed in the TEC. In this way, the chamber allows the fat tissue to grow until it fills all the available space inside the chamber. The volume of the breast is then naturally reconstructed in an autologous way. At the same time, the biomaterial that makes up the TEC is completely resorbable. Patients will be followed regularly for 12 to 24 months. The growth of the flap and the resorption of the CTE will be measured by MRI. Aesthetic criteria of the reconstructed breast, quality of life and patient satisfaction will be evaluated.




Figure 2 - Operating principle of MATTISSE (Regeneration of the adipose tissue then resorption of the implant)

LATTICE MEDICAL is an implantable medical device company that develops and manufactures a breakthrough technology in the field of autologous fat reconstruction. This technology is patented by the Lille University Hospital, with which LATTICE MEDICAL works in close collaboration. The company has about 20 employees and a 3D printing production site dedicated to implantable medical devices.

The first application of its technology concerns breast reconstruction after cancer. One woman in eight is currently affected by breast cancer. In 40% of cases, the treatment is surgical with a complete or partial mastectomy. Only 20% of women will benefit from reconstruction because current techniques (breast implants or autologous surgical techniques) have drawbacks (cumbersome surgical procedure, multiple surgeries) and are costly for the health care system, which limits the number of reconstructions performed on patients. This is why **LATTICE MEDICAL** has developed the implantable medical device **MATTISSE**, which allows the regeneration of autologous fatty tissue and is completely resorbed from the body after breast reconstruction, thus avoiding additional surgeries and long-term sequelae and risks for patients.